WOBURN, Mass., July 28, 2025 (GLOBE NEWSWIRE) -- This press release corrects a version issued on July 25, 2025 that incorrectly listed KCSA Strategic Communications as iSpecimen’s investor relations contact. KCSA is not currently affiliated with iSpecimen Inc. and was mistakenly included in the prior release. The corrected release is below in its entirety.
TSX and OTC: MPVD
TORONTO and NEW YORK, July 28, 2025 /PRNewswire/ -- Mountain Province Diamonds Inc. ("Mountain Province" or the "Company") (TSX: MPVD) (OTC: MPVD) announces today that it has entered into an...
SAN DIEGO, July 28, 2025 (GLOBE NEWSWIRE) -- Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Fiserv, Inc. (NYSE: FI) common stock between July 24, 2024 and July 22, 2025, both dates inclusive (the “Class Period”), have until September 22, 2025 to seek appointment as lead plaintiff of the Fiserv class action lawsuit. Captioned City of Hollywood Police Officers’ Retirement System v. Fiserv, Inc., No. 25-cv-06094 (S.D.N.Y.), the Fiserv class action lawsuit charges Fiserv and certain of Fiserv’s top current and former executives with violations of the Securities Exchange Act of 1934.
Basel, 28 July 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that new data from its Alzheimer’s development portfolio is being presented at the Alzheimer’s Association International Conference (AAIC) in Toronto, Canada (July 27-30). These data exemplify the comprehensive approach Roche is taking in addressing Alzheimer’s across the entire patient journey.
KUALA LUMPUR, Malásia, July 25, 2025 (GLOBE NEWSWIRE) -- A Bitget, principal corretora de criptomoedas e empresa Web3 do mundo, participou da Malaysia Blockchain Week 2025 para fortalecer seus laços com a crescente economia digital do Sudeste Asiático. O evento, realizado no World Trade Centre de Kuala Lumpur, atraiu mais de 3.300 participantes de 20 países, com o apoio de agências malaias como MDEC, o Ministério Digital e a Tourism Malaysia.
WOBURN, Mass., July 25, 2025 (GLOBE NEWSWIRE) -- iSpecimen Inc. (Nasdaq: ISPC) (“iSpecimen” or the “Company”), an online global marketplace that connects scientists requiring biospecimens for medical research with a network of healthcare specimen providers, announced today the closing of its previously announced underwritten public offering of 5,714,283 shares of its common stock (or pre-funded warrants to purchase common stock in lieu thereof) at a public offering price of $0.70 per share (the “Offering”). The aggregate gross proceeds to the Company from the Offering was approximately $4 million, before deducting underwriting discounts and commissions and other offering expenses.
Le groupe Unimot envisage de se lancer dans l’industrie de la défense en investissant dans la nouvelle société PZL Defence, qui se spécialisera dans le développement et la production de drones et de systèmes anti-drones. Le projet sera réalisé en coopération avec PZL Sędziszów, un fabricant expert en composants pour l’industrie de la défense, et un partenaire ukrainien disposant d’une expertise pratique acquise en temps de guerre.
Le groupe Unimot envisage de se lancer dans l’industrie de la défense en investissant dans la nouvelle société PZL Defence, qui se spécialisera dans le développement et la production de drones et de systèmes anti-drones. Le projet sera réalisé en coopération avec PZL Sędziszów, un fabricant expert en composants pour l’industrie de la défense, et un partenaire ukrainien disposant d’une expertise pratique acquise en temps de guerre.
NEW YORK und MAINZ, Deutschland, 25. Juli 2025 — Pfizer Inc. (NYSE: PFE, „Pfizer“) und BioNTech SE (Nasdaq: BNTX, „BioNTech“) gaben heute bekannt, dass der Ausschuss für Humanarzneimittel (Committee for Medicinal Products for Human Use, „CHMP“) der Europäischen Arzneimittel-Agentur (European Medicines Agency, „EMA“) eine positive Beurteilung für die Marktzulassung (Marketing Authorization) des an LP.8.1 angepassten monovalenten COVID-19-Impfstoffs (COMIRNATY® LP.8.1) der Unternehmen für die aktive Immunisierung zur Vorbeugung von COVID-19 verursacht durch SARS-CoV-2 bei Personen ab 6 Monaten ausgesprochen hat. Die Anpassung basiert auf der Empfehlung der Notfall-Taskforce (Emergency Task Force, „ETF“) der EMA, die vorschlägt, COVID-19-Impfstoffe zu aktualisieren, um die LP.8.1-Variante für die Impfkampagne 2025-2026 abzudecken. Die Notfall-Taskforce erklärte: „Eine Anpassung an LP.8.1 wird dabei helfen, die Wirksamkeit der Impfstoffe gegen das sich fortlaufend weiterentwickelnde SARS-CoV-2 aufrechtzuerhalten.“2
Tallinna Vesi kutsub aktsionäre, investoreid, analüütikuid ja teisi huvilisi osalema ettevõtte 2025. aasta teise kvartali ja kuue kuu tulemusi tutvustaval veebiseminaril 1. augustil 2025 kell 11.00. Veebiseminar toimub inglise keeles. Tulemusi tutvustavad AS Tallinna Vesi tegevjuht Aleksandr Timofejev ja finantsdirektor Taavi Gröön.